Health

Moderna administers to first participants in early trials of seasonal influenza vaccine candidates

Each vaccine candidate contains eight mRNAs that target both hemagglutinin and neuraminidase at different doses and ratios.

The first participant was administered in a Phase 1/2 study of Moderna’s seasonality. influenza Vaccine candidates, mRNA-1020 and mRNA-1030, analyzing the safety, responsiveness, and immunogenicity of single doses of mRNA-1020 and mRNA-1030 in healthy adults aged 18 years and older in the United States.

Each vaccine candidate contains eight mRNAs that target both hemagglutinin and neuraminidase at different doses and ratios. Like mRNA-1010, mRNA-1020 and mRNA-1030 are recommended by the World Health Organization for the prevention of influenza, including seasonal influenza A / H1N1, A / H3N2, influenza B / Yamagata and B /. Targets stocks that are. Victoria. Approximately 560 participants are enrolled in the study.

In a press release, Moderna’s Chief Executive Officer, Stephen Bansel, said, “We are pleased to be able to apply Moderna’s mRNA platform to address the long-standing design and manufacturing challenges associated with the development of seasonal influenza vaccines. Achieves broader immunity and higher vaccine efficacy against circulating influenza strains than traditional influenza vaccines. In addition, the flexibility and rapid production capacity of a multi-strain targeting platform allows for predominant circulating influenza. We hope that it will be easier to produce a vaccine that matches the strain. “Distortion.”

There are three main types of influenza virus that infect humans (A, B, C), with influenza A and B causing the most severe morbidity and mortality. In addition, influenza A and B viruses have two major surface glycoproteins, hemagglutinin and neuraminidase, that are essential throughout the viral life cycle.

Previous studies have predicted that targeting both viral proteins may limit the ability of the virus to escape the host’s immune response through mutations, leading to better protection.

Moderna has announced that it will continue to pursue an iterative approach to influenza vaccine development by increasing the level of enhancement aimed at improving the immune response and expanding its immunological scope.

reference

MODERNA announced the first participants to receive the seasonal influenza vaccine candidates for mRNA-1020 and mRNA-1030 in Phase 1/2 trials. Modana. April 11, 2022. Accessed on April 11, 2022. https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-12-Study-with-mRNA-1020-and-mRNA-1030-Seasonal- Influenza-Vaccine-Candidate /default.aspx

ExBulletin

Moderna administers to first participants in early trials of seasonal influenza vaccine candidates